Melissa Baird Sells 17,625 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report) COO Melissa Baird sold 17,625 shares of Hims & Hers Health stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $20.51, for a total value of $361,488.75. Following the completion of the transaction, the chief operating officer now owns 585,800 shares of the company’s stock, valued at approximately $12,014,758. The sale was disclosed in a document filed with the SEC, which is available at this link.

Melissa Baird also recently made the following trade(s):

  • On Tuesday, July 9th, Melissa Baird sold 17,625 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.42, for a total transaction of $359,902.50.
  • On Tuesday, June 4th, Melissa Baird sold 17,625 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.42, for a total value of $359,902.50.
  • On Thursday, May 2nd, Melissa Baird sold 11,750 shares of Hims & Hers Health stock. The stock was sold at an average price of $12.08, for a total transaction of $141,940.00.

Hims & Hers Health Price Performance

Shares of HIMS stock traded up $0.16 on Tuesday, hitting $20.67. The company’s stock had a trading volume of 5,037,407 shares, compared to its average volume of 7,409,410. The stock has a market capitalization of $4.44 billion, a price-to-earnings ratio of -2,050.50 and a beta of 1.08. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $25.74. The firm’s fifty day moving average price is $18.61 and its 200-day moving average price is $14.07.

Hims & Hers Health (NYSE:HIMSGet Free Report) last released its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.03. The company had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The firm’s revenue was up 45.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.05) EPS. Analysts predict that Hims & Hers Health, Inc. will post 0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HIMS has been the subject of several analyst reports. Jefferies Financial Group boosted their price objective on Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. Canaccord Genuity Group started coverage on Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised their price objective on Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a research note on Tuesday, May 7th. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, May 22nd. Finally, Bank of America increased their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. Seven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

View Our Latest Report on HIMS

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Forerunner Ventures Management LLC bought a new stake in shares of Hims & Hers Health during the 4th quarter worth $86,836,000. Farallon Capital Management LLC grew its holdings in Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after buying an additional 1,634,000 shares during the last quarter. M&G Plc acquired a new stake in shares of Hims & Hers Health in the first quarter worth $8,232,000. Vanguard Group Inc. increased its holdings in shares of Hims & Hers Health by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after purchasing an additional 428,671 shares during the period. Finally, Mckinley Capital Management LLC raised its holdings in Hims & Hers Health by 34.9% in the 4th quarter. Mckinley Capital Management LLC now owns 896,020 shares of the company’s stock valued at $7,975,000 after acquiring an additional 231,867 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Featured Stories

Insider Buying and Selling by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.